Company Aviragen Therapeutics Inc Nasdaq
Equities
US0906941002
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
03-14 | Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-14 | Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024 |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Recombinant Protein Vaccines
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 7 | 100.0 % | +6,796.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 31/12/03 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 18/12/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
James Cummings
CTO | Chief Tech/Sci/R&D Officer | - | 26/09/21 |
Chief Tech/Sci/R&D Officer | - | 30/08/22 | |
Edward Berg
LAW | General Counsel | - | 13/02/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 24/10/19 |
Elaine Heron
BRD | Director/Board Member | 76 | 24/08/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
Sean Tucker
FOU | Founder | - | 31/12/03 |
David Wheadon
BRD | Director/Board Member | 66 | 20/04/21 |
Director/Board Member | 73 | 03/08/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 177,345,031 | 174,833,551 ( 98.58 %) | 507,020 ( 0.2859 %) | 98.58 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- VXRT Stock
- Stock
- Company Aviragen Therapeutics Inc